Reply: Spastic paraplegia in ‘dominant optic atrophy plus’ phenotype due to OPA1 mutation by Yu-Wai-Man, Patrick & Chinnery, Patrick F.
BRAIN
A JOURNAL OF NEUROLOGY
LETTERTO THE EDITOR
Reply: Spastic paraplegia in ‘dominant optic atrophy plus’ phenotype due to
OPA1 mutation
Patrick Yu-Wai-Man
1,2 and Patrick F. Chinnery
1,3
1 Mitochondrial Research Group, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, NE1 3BZ, UK
2 Department of Ophthalmology, Royal Victoria Inﬁrmary, Newcastle upon Tyne, NE1 4LP, UK
3 Department of Neurology, Royal Victoria Inﬁrmary, Newcastle upon Tyne, NE1 4LP, UK
Correspondence to: Prof Patrick Chinnery,





Sir, Pretegiani et al. (2011) describe a 28-year-old female with
early-onset optic atrophy who subsequently developed slowly
progressive spastic paraplegia. Electrophysiological studies did not
suggest a peripheral neuropathy and additional investigations
excluded a primary demyelinating process as the cause of her
neurological deﬁcits. Interestingly, this patient was eventually
found to harbour a previously reported c.2708_2711delTTAG
pathogenic deletion in exon 27 of OPA1—the causative gene in
the majority of patients with autosomal dominant optic atrophy.
Based on this isolated observation, it is difﬁcult to conclude that
migraine and Duane retraction syndrome are causally related to
this speciﬁc OPA1 mutation. In our original study in Brain, 5%
of patients with dominant optic atrophy plus (DOA+) suffered
from migraine, which is less than the background prevalence in
the general population (Yu-Wai-Man et al., 2010). Duane retrac-
tion syndrome is the most common of the congenital cranial dys-
innervation disorders, and the underlying developmental defect is
an absent or hypoplastic sixth cranial nerve, with aberrant innerv-
ation of the lateral rectus muscle by a branch of the third cranial
nerve (Oystreck et al., 2011). Multiple chromosomal loci have
been implicated and one gene, CHN1 (MIM 118423), has so far
been identiﬁed in families with autosomal dominant Duane retrac-
tion syndrome.
This report by Pretegiani et al. (2011) strengthens the emerging
pathophysiological link between OPA1 mutations and corticospinal
tract dysfunction. It also highlights two intriguing features seen in
most families manifesting DOA+ phenotypes: incomplete
penetrance and the phenotypic variability seen with the same
pathogenic OPA1 mutation. The proband’s father and sister
were described as asymptomatic mutational carriers, implying
non-penetrance for both optic atrophy and spastic paraplegia. It
would be interesting to know what actual tests were carried out
on these two family members since the criteria for establishing
non-penetrance is somewhat linked to how far one decides to
investigate. When examined closely, visually asymptomatic
OPA1 carriers will often demonstrate subtle, but deﬁnite, impair-
ment in optic nerve function. Furthermore, in borderline cases,
optical coherence tomography imaging can prove a useful adjunct,
revealing a reduction in peripapillary retinal nerve ﬁbre layer thick-
ness more marked temporally in the distribution of the papilloma-
cular bundle (Yu-Wai-Man et al., 2011). In relation to the
neurological sequelae seen with OPA1 disease, rather strikingly,
we recently found that one in four mutational carriers with pure
dominant optic atrophy (i.e. isolated optic atrophy) had prolonged
central motor conduction times with transcranial magnetic stimu-
lation (Baker et al., 2010). These ﬁndings clearly indicate the pres-
ence of subclinical corticospinal tract dysfunction in a sizeable
patient subgroup, with those individuals manifesting spastic para-
plegia only representing the ‘tip of the iceberg’. This phenotypic
variability, ranging from true non-penetrance, to subclinical and
clinically overt disease, was somewhat to be expected, reﬂecting
the inﬂuence of secondary factors on the pathological expression
of the OPA1 mutation. Future studies will hopefully clarify the
nature of these modulatory inﬂuences and the cellular mechanisms
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practical level, patients with unexplained spastic paraplegia should
undergo a comprehensive neuro-ophthalmological assessment to
speciﬁcally look for evidence of optic nerve dysfunction. If present,
OPA1 screening is warranted especially if a muscle biopsy also
conﬁrms histochemical and molecular features of mitochondrial
dysfunction.
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